GlaxoSmithKline

28 May 2025

28 May 2025

Data to be part of a planned US FDA filing in H2 2025

PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee

28 May 2025

Data to be part of a planned US FDA filing in H2 2025

23 May 2025

23 May 2025

Positive opinion supported by superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7.

Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma

23 May 2025

Positive opinion supported by superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7.

Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma

19 May 2025

Second major approval for Blenrep combinations, with more expected in 2025

19 May 2025

19 May 2025

Second major approval for Blenrep combinations, with more expected in 2025

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

14 May 2025

Affecting up to 5% of the global population, SLD represents an area of significant unmet medical need with limited treatment options.

GSK provides update on belrestotug development programme

14 May 2025

GSK with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug.

14 May 2025

14 May 2025

GSK with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug.

08 May 2025

08 May 2025

Late-breaking results presented at the European Association for the Study of the Liver (EASL) Congress 2025

View details about the software product Informachine News Trackers